Tagged with Talent,

China In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft for a new BIOSECURE Act.   While the final version of the law, signed by President Donald Trump in December…

Taiwan Boston Scientific’s Dan Silver reflects on his global leadership journey and the evolution of the company’s presence in one of Asia’s most advanced healthcare systems. Silver discusses Boston Scientific’s growth drivers, Taiwan’s strategic role in Asia-Pacific, and striking the balance between innovation, digital health, and value-based care. He also shares…

Taiwan Since arriving at Organon Taiwan two years ago, Robert Mitchell has focused on growing patient access, revenue, and investments while strengthening the team. Robert explains how he is prioritising government partnerships, sustainable supply chains, and women’s health innovation, while fostering an inclusive culture, digitalisation, and talent development.   We are…

USA North Carolina has become a focal point for the next phase of biopharmaceutical manufacturing, and FUJIFILM Biotechnologies is placing a significant bet on that momentum. Laurie Braxton discusses how the combination of large-scale capacity, experienced talent, and a tightly integrated site network is shaping a long-term manufacturing platform designed for…

LatAm Fernando Almeida, EVP China & International Markets, discusses his global pharma career and Chiesi’s evolution into a high-performing, innovation-led group. He highlights strong double-digit growth, disciplined investment, and expansion across China and Latin America, underpinned by access-driven strategies, talent mobility, and long-term patient impact.   To become a strong and…

LatAm Raphaël Chin-Fo-Sieeuw, Vice President Life Sciences and Healthcare Americas, DHL Group outlines the Americas as a core growth region, with strong momentum in Latin America. He details DHL’s multi-billion-Euro investment in cold chain infrastructure, digitalisation, talent, and sustainability to support advanced therapies, evolving supply chains, and increasingly complex logistics demands…

Hong Kong Amy Ho, General Manager of Roche Pharma Hong Kong, returns to the city with a unique blend of diagnostics and pharmaceutical experience at a moment when the healthcare system is redefining its future. Drawing on years of regional leadership, she offers a clear view of how Hong Kong can strengthen…

Brazil Marco Billi, International CEO of Eurofarma, shares his perspective on the company’s evolution from a Brazilian CMO (Contract Manufacturing Organisation) into one of Latin America’s most internationally active pharmaceutical groups. Billi discusses how operational discipline, long-term investment, and a strong global market mindset have underpinned Eurofarma’s sustained growth, while outlining…

Taiwan Cathy Su, General Manager for Taiwan, Hong Kong/Macau & Singapore at Gilead Sciences, reflects on her nineteen-year tenure with the biopharmaceutical company, progressing from market analytics to multi-market leadership. She discusses Gilead’s strategic evolution from virology specialist to diversified oncology player, the complexities of navigating diverse Asian healthcare systems, and…

France Founded in 1973, IFIS stands at the intersection of education, industry, and public policy, shaping the capabilities that underpin France’s global health leadership. Evolving from its origins as a training fund manager into a multifaceted institution, IFIS today drives professional excellence across pharmaceuticals, medtech, and cosmetics, bridging technical expertise, digital…

Hong Kong With a strong heritage in Asia, DKSH has evolved into a leading force in connecting global healthcare innovation with local patient access. In this interview, Wai Ting Fong, VP Healthcare and Head Country Management at DKSH Hong Kong, shares how the organisation is shaping the region’s healthcare landscape, from pioneering…

Switzerland Helsinn has recently entered one of the most consequential transformations in its history. As it prepares for a new transition at the helm of the company, Executive Chairman Riccardo Braglia and outgoing Group CEO Melanie Rolli reflect on a period marked by strategic separation, operational reinvention, and renewed therapeutic ambition.…